Erick Lucera - 12 Feb 2026 Form 4 Insider Report for Dyne Therapeutics, Inc. (DYN)

Role: Chief Financial Officer
Signature: /s/ Ron Caponigro, Attorney-in-Fact
Issuer symbol: DYN
Transactions as of: 12 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Feb 2026, 17:08:46 UTC
Previous filing: 18 Dec 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lucera Erick	Chief Financial Officer	C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM	/s/ Ron Caponigro, Attorney-in-Fact	17 Feb 2026	0001697616

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DYN	Common Stock	Award	$0	+65,000	+98%	$0.000000	131,100	12 Feb 2026	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DYN	Stock Option (Right to Buy)	Award	$0	+105,000		$0.000000	105,000	12 Feb 2026	Common Stock	105,000	$16.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of Common Stock issuable under 65,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026.
F2	Includes 131,100 unvested RSUs.
F3	This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030.